The U.S. Food and Drug Administration (FDA) has given the green light to Amgen’s monoclonal antibody Bkemv, the first interchangeable biosimilar for Alexion’s top-selling drug Soliris. This provides a pathway for more affordable treatments for rare blood diseases. Let’s take a closer look at what this means for the industry, medical practitioners, and patients. Deciphering […]
FDA Approves Amgen’s First Interchangeable Biosimilar Read More »
Tuesday brought good news for asthma sufferers and the healthcare community alike, courtesy of GSK. The pharmaceutical firm announced the successful reduction of annual asthma attacks in two pivotal clinical trials of its experimental antibody treatment named Depemokimab. The trials involved adults and adolescents afflicted with a form of severe asthma. GSK’s newly developed long-lasting
GSK’s New Asthma Drug Clears Two Phase 3 Trials Read More »
In an exciting development for the biopharma industry, Sanofi, OpenAI, and Formation Bio have announced a unique partnership aiming to develop AI-powered drug R&D software. This strategic alliance is a testament to the increasingly intertwined future of the technology and pharmaceutical sectors. This announcement follows closely on the heels of OpenAI’s other significant alliance with
Big Pharma and Tech: Unlocking AI for Drug Development Read More »
Walgreens, a powerhouse in the retail and wholesale pharmaceutical sector, embarked on an unprecedented path with an impressive service upgrade – the incorporation of gene and cell therapies. This strategy extends Walgreens’ existing service portfolio and significantly advances healthcare. Let’s explore this groundbreaking endeavor and what it means for customers. Walgreens is expanding its specialty
Walgreens Diversifies into Gene and Cell Therapies Read More »
The Food and Drug Administration (FDA) has recently been the center of attention in the biopharmaceutical world, pushing for a notable shift in the discourse surrounding biosimilars. The federal agency has openly campaigned for the abolition of ‘interchangeability‘ – a term it perceives as causing more confusion than clarity and adversely impacting the market penetration
FDA-Approved Swap-In Biosimilars: Progress or Barriers? Read More »
The United States is currently experiencing an unsettling wave of drug shortages, as reported by the American Society of Health-System Pharmacists (ASHP). This ongoing crisis is putting the flexibility and robustness of our healthcare system to the test amid an unparalleled rise in medication shortages. According to the ASHP report, the first three months of
The U.S. Battles Against Unprecedented Drug Shortages Read More »
In the realm of healthcare, the patient journey stands as a fundamental framework, guiding the interaction between patients, healthcare providers, and the wider health ecosystem. But within the vast spectrum of patient care, not all journeys are equal. Some are marked by urgency, the relentless pursuit of health, and the stark realities of a life
Understanding Patient Journeys: A Comparative Study Read More »
With the arrival of spring, the excitement for the Pharmaceutical Management Science Association’s 48th Annual Conference, set to kick off during the first week of May 2024, starts to build. This year, the bustling city of Denver, Colorado gets to play host to this prestigious event, a much-anticipated gathering for pharmaceutical data professionals across the
The Countdown Begins: Preparing for the PMSA 2024 Conference Read More »
As our most recently concluded conference, Access USA drew its curtains, we stood marveling at the culmination of an event that served as a confluence of experts from various disciplines within the life sciences domain. This monumental conference amalgamated three industry-leading events, all directed towards one significant arena – patient access. They created a comprehensive
Hub East: Promoting Collaboration for Program Success Read More »
As we step further into the fray and journey into the world of healthcare, one startling revelation makes itself known – cost-related medication non-adherence is a reality that 1 in 6 US patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD) have to deal with, according to a recent article published by The American Journal of
Cost-Related Medication Non-Adherence in the US Read More »